Senseonics Target of Unusually Large Options Trading (NYSE:SENS)

Senseonics Holdings, Inc. (NYSE:SENS) saw some unusual options trading on Monday. Stock traders purchased 4,425 call options on the company. This represents an increase of 63% compared to the typical daily volume of 2,719 call options.

Wall Street Analyst Weigh In

Several equities analysts recently commented on SENS shares. StockNews.com started coverage on Senseonics in a research report on Thursday, December 26th. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Price Performance

Shares of SENS traded up $0.05 during midday trading on Monday, reaching $0.90. The stock had a trading volume of 1,711,615 shares, compared to its average volume of 14,655,776. The company’s 50-day moving average is $0.84 and its 200 day moving average is $0.53. Senseonics has a 12-month low of $0.25 and a 12-month high of $1.40. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The company has a market capitalization of $536.98 million, a price-to-earnings ratio of -6.95 and a beta of 0.69.

Insider Activity at Senseonics

In related news, CEO Timothy T. Goodnow acquired 315,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the purchase, the chief executive officer now owns 11,310,355 shares in the company, valued at $3,506,210.05. This trade represents a 2.86 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Frederick T. Sullivan acquired 124,933 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the purchase, the chief financial officer now owns 2,478,844 shares in the company, valued at $941,960.72. This trade represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Senseonics

Hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Senseonics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after acquiring an additional 179,103 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Senseonics in the 3rd quarter valued at about $117,000. Ridgecrest Wealth Partners LLC bought a new stake in shares of Senseonics in the 4th quarter valued at about $60,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Senseonics in the 4th quarter valued at about $720,000. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.